CXCL17 Polyclonal antibody

CXCL17, also known as C-X-C motif chemokine 17, is a relatively newly discovered member of the CXC chemokine family, which plays a multifaceted role in immune responses and other biological processes. CXCL17 has been implicated in several human pathologies, and its role in mediating immune responses is of particular interest. It is involved in the recruitment of immune cells, angiogenesis, and control of microorganisms at mucosal barriers . It is also known to be involved in tumor angiogenesis and has shown both proinflammatory and anti-inflammatory effects. CXCL17 is highly expressed in the gastric mucosa and other mucosal tissues. Its receptor was identified as GPR35 and named CXCR8, although the functional role of this interaction is not yet fully understood. CXCL17's expression is associated with both disease progression and protection in various diseases. It has been linked to pulmonary fibrosis, asthma, lung cancer, and hepatic cancer, where increased expression is associated with disease progression. Conversely, it may play a protective role in pancreatic cancer, autoimmune encephalomyelitis, and viral infections. Research has shown that CXCL17 promotes neutrophil trafficking and plays a role in the early proinflammatory response by facilitating the recruitment of neutrophils to the site of insult . It also exhibits chemoattractant abilities targeting monocytes and macrophages and can induce the production of proangiogenic factors such as vascular endothelial growth factor A from treated monocytes